Full Prescribing Info
Pharmacology: Pharmacodynamics: Mechanism of Action: Doripenem is a synthetic carbapenem antibacterial agent.
Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death.
In vitro doripenem showed little potential to antagonize or be antagonized by other antibacterial agents. Additive activity or weak synergy with amikacin and levofloxacin has been seen for Pseudomonas aeruginosa and for gram-positive bacteria with daptomycin, linezolid, levofloxacin and vancomycin.
Pharmacokinetic/Pharmacodynamic Relationship: Similar to other β-lactam antimicrobial agents, the time that the plasma concentration of doripenem exceeds the MIC (%T>MIC) of the infecting organism has been shown to best correlate with efficacy in preclinical pharmacokinetic/pharmacodynamic (PK/PD) studies. Monte Carlo simulations using pathogen susceptibility results from completed phase 3 trials and population PK data indicated that the %T>MIC target of 35% was achieved in >90% of patients with nosocomial pneumonia, complicated urinary tract infections and complicated intra-abdominal infections, for all degrees of renal function.
Extending the infusion time of Doribax to 4 hrs maximizes the %T>MIC for a given dose and is the basis for the option to administer 4-hr infusions in patients with nosocomial pneumonia including ventilator-associated pneumonia. In seriously ill patients or those with an impaired immune response, a 4-hr infusion time may be more suitable when the MIC of doripenem for the known or suspected pathogen(s) has been shown or is expected to be >0.5 mg/L, in order to reach a target attainment of 50% T>MIC in at least 95% of the patients. Monte Carlo simulations supported the use of 500 mg 4-hr infusions every 8 hrs in subjects with normal renal function for target pathogens with doripenem MICs ≤4 mg/L.
Mechanisms of Resistance: Bacterial resistance mechanisms that effect doripenem include active substance inactivation by carbapenem-hydrolyzing enzymes, mutant or acquired PBPs, decreased outer membrane permeability and active efflux. Doripenem is stable to hydrolysis by most β-lactamases, including penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of relatively rare carbapenem hydrolyzing β-lactamases. Species resistant to other carbapenems do generally express co-resistance to doripenem. Methicillin-resistant staphylococci should always be considered as resistant to doripenem. As with other antimicrobial agents, including carbapenems, doripenem has been shown to select for resistant bacterial strains.
Breakpoints: Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows: See table.

Click on icon to see table/diagram/image

Susceptibility: The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.
Localized clusters of infections due to carbapenem-resistant organisms have been reported in the European Union. The information as follows gives only approximate guidance on the probability as to whether the microorganism will be susceptible to doripenem or not.
Commonly Susceptible Species: Gram-positive Aerobes: Enterococcus faecalis1,2, Staphylococcus aureus (methicillin-susceptible strains only)1,4, Staphylococcus spp (methicillin-susceptible strains only)4, Streptococcus pneumoniae1, Streptococcus spp
Gram-negative Aerobes: Citrobacter diversus, Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae1, Haemophilus influenzae1, Escherichia coli, Klebsiella pneumoniae1, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis1, Proteus vulgaris, Providencia rettgeri, Providencia stuartii, Salmonella spp, Serratia marcescens, Shigella spp.
Anaerobes: Bacteroides fragilis1, Bacteroides caccae1, Bacteroides ovatus, Bacteroides uniformis1, Bacteroides thetaiotaomicron1, Bacteroides vulgatus1, Bilophila wadsworthia, Peptostreptococcus micros1, Porphyromonas spp, Prevotella spp, Sutterella wadsworthenis.
Species for which acquired resistance may be a problem: Acinetobacter baumannii1, Acinetobacter spp, Burkholderia cepacia2,3, Pseudomonas aeruginosa1.
Inherently Resistant Organisms: Gram-positive Aerobes: Enterococcus faecium.
Gram-negative Aerobes: Stenotrophomonas maltophilia, Legionella spp.
1Species against which activity has been demonstrated in clinical studies.
2Species that show natural intermediate susceptibility.
3Species with >50% acquired resistance in one or more Member State.
4All methicillin-resistant staphylococci should be regarded as resistant to doripenem.
Pharmacokinetics: The mean Cmax and AUC0-∞ of doripenem in healthy subjects across studies following administration of 500 mg over 1 hr are approximately 23 mcg/mL and 36 mcg·hr/mL, respectively. The mean Cmax and AUC0-∞ of doripenem in healthy subjects across studies following administration of 500 mg and 1 g over 4 hrs are approximately 8 mcg/mL and 17 mcg/mL and 34 mcg·hr/mL and 68 mcg·hr/mL, respectively. There is no accumulation of doripenem following multiple IV infusions of either 500 mg or 1 g administered every 8 hrs for 7-10 days in patients with normal renal function.
Distribution: The average binding of doripenem to plasma proteins was approximately 8.1% and is independent of plasma concentrations. The volume of distribution at steady-state is approximately 16.8 L, similar to extracellular fluid volume in man. Doripenem penetrates well into several body fluids and tissues eg, uterine tissue, retroperitoneal fluid, prostatic tissue, gallbladder tissue and urine.
Metabolism: Metabolism of doripenem to a microbiologically inactive ring-opened metabolite occurs primarily via dehydropeptidase-I. Doripenem undergoes little to no cytochrome P-450 (CYP450) mediated metabolism. In vitro studies have determined that doripenem does not inhibit or induce the activities of CYP isoforms 1A2, 2A6, 2C9, 2C19, 2D6, 2E1 or 3A4.
Elimination: Doripenem is primarily eliminated unchanged by the kidneys. Mean plasma terminal elimination half-life of doripenem in healthy young adults is approximately 1-hr and plasma clearance is approximately 15.9 L/hr. Mean renal clearance is 10.3 L/hr. The magnitude of this value, coupled with the significant decrease in the elimination of doripenem seen with concomitant probenecid administration, suggests that doripenem undergoes glomerular filtration, tubular secretion and reabsorption. In healthy young adults given a single 500-mg dose of Doribax, 71% and 15% of the dose was recovered in urine as unchanged active substance and ring-opened metabolite, respectively. Following the administration of a single 500-mg dose of radiolabeled doripenem to healthy young adults, <1% of the total radioactivity was recovered in faeces. The pharmacokinetics of doripenem are linear over a dose range of 500 mg to 1 g when IV infused over either 1 or 4 hrs.
Renal Insufficiency: Following a single 500-mg dose of Doribax, doripenem AUC increased 1.6-, 2.8- and 5.1-fold in subjects with mild (CrCl 51-79 mL/min), moderate (CrCl 31-50 mL/min) and severe renal impairment (CrCl≤30 mL/min), respectively, compared to age-matched healthy subjects with normal renal function (CrCl>80 mL/min). AUC of the microbiologically inactive ring-opened metabolite is expected to be considerably increased in patients with severe renal impairment compared with healthy subjects. Dosage adjustment is necessary in patients with moderate and severe renal impairment (see Dosage & Administration).
AUCs of doripenem and of the microbiologically inactive ring-opened metabolite are substantially increased in patients who require haemodialysis compared with healthy subjects. In a study where 6 subjects with end stage renal disease on haemodialysis received a single dose of 500-mg doripenem by IV infusion, the amount of doripenem removed during the 4-hr haemodialysis session was 231 mg (46% of the dose).
Hepatic Impairment: The pharmacokinetics of doripenem in patients with hepatic impairment have not been established. As doripenem does not appear to undergo hepatic metabolism, the pharmacokinetics of Doribax is not expected to be affected by hepatic impairment.
Elderly: The impact of age on the pharmacokinetics of doripenem was evaluated in healthy elderly male and female subjects (66-84 years). Doripenem AUC increased by 49% in the elderly relative to young adults. These changes were mainly attributed to age-related changes in renal function. No dosage adjustment is necessary in elderly patients, except in cases of moderate to severe renal insufficiency (see Dosage & Administration).
Gender: The effect of gender on the pharmacokinetics of doripenem was evaluated in healthy male and female subjects. Doripenem AUC was 15% higher in females compared to males. No dosage adjustment is recommended based on gender.
Race: The effect of race on doripenem pharmacokinetics was examined through a population pharmacokinetic analysis. No significant difference in mean doripenem clearance was observed across race groups and therefore, no dosage adjustment is recommended for race.
Toxicology: Preclinical Safety Data: Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity. However, because of the design of the repeat dose toxicity studies and differences in pharmacokinetics in animals and humans, continuous exposure of animals was not assured in these studies.
No reproductive toxicity was observed in studies performed in rats and rabbits. However, these studies are of limited relevance because studies were performed with single daily dosing resulting in <1/10 of daily doripenem exposure duration in animals.
Treatment of the following infections in adults (see Precautions and Pharmacology: under Actions): Nosocomial pneumonia (including ventilator-associated pneumonia), complicated intra-abdominal infections, complicated urinary tract infections (UTI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Dosage/Direction for Use
The recommended dosage and administration by infection is as follows: Nosocomial Pneumonia Including Ventilator-Associated Pneumonia: 500 mg every 8 hrs for 1 or 4 hrs*.
Complicated Intra-abdominal Infection: 500 mg every 8 hrs for 1 hr.
Complicated UTI, Including Pyelonephritis: 500 mg every 8 hrs for 1 hr.
*Based mainly on PK/PD considerations, a 4-hr infusion time may be more suitable for infection with less susceptible pathogens (see Pharmacology: Pharmacodynamics under Actions). This dosing regimen should also be considered in particularly severe infections.
For infusion solution shelf-life, see Shelf-Life under Storage.
The usual treatment duration of doripenem therapy is 5-14 days and should be guided by the severity, site of the infection and the patient's clinical response. Doripenem was given for up to 14 days in clinical studies and the safety of longer durations of therapy has not been established. After commencing treatment with IV doripenem, a switch to appropriate oral therapy to complete the treatment course is possible once clinical improvement has been established.
Paediatrics: Doribax is not recommended for use in children <18 years due to a lack of safety and efficacy data.
Impaired Renal Function: In patients with mild renal impairment [ie, creatinine clearance (CrCl) is 51-79 mL/min], no dosage adjustment is necessary. In patients with moderate renal impairment (CrCl 30 to <50 mL/min), the dosage of Doribax should be 250 mg every 8 hrs. In patients with severe renal impairment (CrCl <30 mL/min), the dosage should be Doribax 250 mg every 12 hrs. Due to limited clinical data and an expected increased exposure of doripenem and its metabolite, Doribax should be used with caution in patients with severe renal impairment (see Pharmacokinetics under Actions).
Patients on Dialysis: Doribax is haemodialyzable; however, there is insufficient information to make dose adjustment recommendations in patients on dialysis. Therefore, Doribax is not recommended for patients on any type of dialysis (see Pharmacokinetics under Actions).
Elderly (≥65 years): No dosage adjustment is necessary in elderly patients, except in cases of moderate to severe renal insufficiency (see Impaired Renal Function and Pharmacokinetics under Actions).
Impaired Hepatic Function: No dosage adjustment is necessary.
Administration: Doribax is to be reconstituted and then further diluted (see Cautions for Usage) prior to administration by IV infusion over a period of 1 or 4 hrs.
No case of overdose has been reported. In the event of overdose, Doribax should be discontinued and general supportive treatment given until renal elimination takes place. Doribax can be removed by haemodialysis; however, no information is available on the use of haemodialysis to treat overdose.
Hypersensitivity to doripenem or any other carbapenem antibacterial agent; severe hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to any other type of β-lactam antibacterial agent (eg, penicillins or cephalosporins).
Special Precautions
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have occurred in patients receiving β-lactam antibiotics. Before therapy with Doribax is started, careful inquiry should be made concerning a previous history of hypersensitivity reactions to other active substances in this class or to β-lactam antibiotics. Doribax should be used with caution in patients with such history. Should a hypersensitivity reaction to Doribax occur, it should be discontinued immediately and appropriate measures taken. Serious acute hypersensitivity (anaphylactic) reactions require immediate emergency treatment.
Seizures have infrequently been reported during treatment with other carbapenems.
Pseudomembranous colitis due to Clostridium difficile has been reported with Doribax as with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of Doribax (see Adverse Reactions).
Administration of doripenem, like other antibiotics, has been associated with emergence and selection of strains with reduced susceptibility. Patients should be carefully monitored during therapy. If superinfection occurs, appropriate measures should be taken. Prolonged use of Doribax should be avoided.
When Doribax was used investigationally via inhalation, pneumonitis occurred. Therefore, Doribax should not be administered by this route.
Description of the Patient Population Treated in Clinical Studies: In 2 clinical trials of patients with nosocomial pneumonia (N=979), 60% of the clinically-evaluable Doribax-treated patients had ventilator-associated pneumonia (VAP). Of these, 50% had late-onset VAP (defined as that occurring after 5 days of mechanical ventilation), 54% had an Acute Physiology and Chronic Health Evaluation (APACHE) II score >15 and 32% received concomitant aminoglycosides(76% for >3 days).
In 2 clinical trials of patients with complicated intra-abdominal infections (N=962) the most common anatomical site of infection in microbiologically-evaluable Doribax-treated patients was the appendix (62%). Of these, 51% had generalised peritonitis at baseline. Other sources of infection included colon perforation (20%), complicated cholecystitis (5%) and infections at other sites (14%). Eleven percent had an APACHE II score of >10, 9.5% had postoperative infections, 27% had single or multiple intra-abdominal abscesses and 4% had concurrent bacteraemia at baseline.
In 2 clinical trials of patients with complicated urinary tract infections (N=1179), 52% of microbiologically-evaluable Doribax-treated patients had complicated lower urinary tract infections and 48% had pyelonephritis, of which 16% were complicated. Overall, 54% of patients had a persistent complication, 9% had concurrent bacteraemia and 23% were infected with a levofloxacin-resistant uropathogen at baseline.
The experience in patients who are severely immunocompromised, receiving immunosuppressive therapy and patients with severe neutropenia is limited since this population was excluded from phase 3 trials.
Effects on the Ability to Drive or Operate Machinery: No studies on the effects of Doribax on the ability to drive and use machines have been performed. Based on reported adverse drug reactions, it is not anticipated that Doribax will affect the ability to drive and use machines.
Use in pregnancy & lactation: For doripenem, limited clinical data on exposed pregnancies are available. Animal studies are insufficient with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see Toxicology: Preclinical Safety Data). The potential risk for humans is unknown. Doribax should not be used during pregnancy unless clearly necessary.
It is unknown whether doripenem is excreted in human breast milk. A study in rats has shown that doripenem and its metabolite are transferred to milk. A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with Doribax should be made taking into account the benefit of breastfeeding to the child and the benefit of Doribax therapy to the woman.
Adverse Reactions
In 3142 adult patients (1817 of which received Doribax) evaluated for safety in phase 2 and phase 3 clinical trials, adverse reactions due to Doribax 500 mg every 8 hrs occurred at rate of 32%. Doribax was discontinued because of adverse drug reactions in 0.1% of patients overall. Adverse drug reactions that led to Doribax discontinuation were nausea (0.1%), diarrhoea (0.1%), pruritus (0.1%), vulvomycotic infection (0.1%), increased hepatic enzyme (0.2%) and rash (0.2%). The most common adverse reactions were headache (10%), diarrhoea (9%) and nausea (8%).
Adverse drug reactions due to Doribax 500 mg are listed as follows by frequency category. Frequency categories are defined as follows: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to <1/100).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Adverse Drug Reactions Identified During Clinical Trials with Doribax: Infections and Infestation: Common: Oral candidiasis, vulvomycotic infection.
Immune System Disorders: Uncommon: Hypersensitivity reactions (see Precautions).
Nervous System Disorders: Very Common: Headache.
Vascular Disorders: Common: Phlebitis.
Gastrointestinal Disorders: Common: Nausea, diarrhoea. Uncommon: C. difficile colitis (see Precautions).
Hepatobiliary Disorders: Common: Increased hepatic enzyme.
Skin and Subcutaneous Tissue Disorders: Common: Pruritus, rash.
Adverse Drug Reactions Identified During Post-Marketing Experience with Doribax: Blood and the Lymphatic System Disorders: Frequency Not Known: Neutropenia.
Immune System Disorders: Frequency Not Known: Anaphylaxis (see Precautions).
Drug Interactions
Doripenem undergoes little to no Cytochrome P-450 (CYP450) mediated metabolism. Based on in vitro studies it is not expected that doripenem will inhibit or induce the activities of CYP450. Therefore, no CYP450-related drug interactions are to be expected (see Pharmacokinetics under Actions).
Carbapenem antibacterial agents may reduce serum valproic acid concentrations. Serum concentrations of valproic acid should be monitored if Doribax is administered concomitantly with valproic acid.
Probenecid competes with doripenem for renal tubular secretion and reduces the renal clearance of doripenem. In an interaction study, the mean doripenem AUC increased by 75% following co-administration with probenecid. Therefore, co-administration of probenecid with Doribax is not recommended. An interaction with other drugs eliminated by renal tubular secretion cannot be excluded.
Incompatibilities: Doribax must not be mixed with other medicinal products except those mentioned in Shelf-life under Storage.
Caution For Usage
Each vial is for single use only.
Doribax is reconstituted and then further diluted prior to infusion.
Preparation of 500-mg Dose of Solution for Infusion: Add 10 mL of sterile water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection to the vial and shake it to form a suspension.
Inspect the suspension visually for foreign matter. Note: The suspension is not for direct infusion.
Withdraw the suspension using a syringe and needle and add it to an infusion bag containing 100 mL of either sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection and mix to complete dissolution. Infuse all of this solution to administer a 500-mg dose of doripenem.
Preparation of 250-mg Dose of Solution for Infusion for Patients with Moderate or Severe Renal Impairment: Add 10 mL of sterile water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection to the vial and shake it to form a suspension.
Inspect the suspension visually for foreign matter. Note: The suspension is not for direct infusion.
Withdraw the suspension using a syringe and needle and add it to an infusion bag containing 100 mL of either sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection and mix to complete dissolution. Remove 55 mL of this solution from the infusion bag and discard. Infuse all of the remaining solution to administer a 250-mg dose of doripenem.
Doribax solutions for infusion range from clear, colourless solutions to solutions that are clear and slightly yellow. Variations in colour within this range do not affect the potency of the product.
Any unused product or waste material should be disposed of in accordance with local requirements.
Do not store above 30°C.
Shelf-Life: Storage of Reconstituted Solutions: Upon reconstitution with sterile water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection, Doribax suspension in the vial may be held for up to 1 hr below 30°C prior to transfer and dilution in the infusion bag.
Following dilution in the infusion bag with sodium chloride 9 mg/mL (0.9%) solution for injection or dextrose 50 mg/mL (5%) solution for injection, Doribax infusions stored at controlled room temperature (25±2°C) or under refrigeration should be completed according to the times in the following: Sodium chloride 9 mg/mL (0.9%) solution for injection: Solution stored at 25±2°C: 12 hrs; solution stored in a refrigerator (2°-8°C): 72 hrs*.
+Dextrose 50 mg/mL (5%) solution for injection: Solution stored at 25±2°C: 4 hrs; solution stored in a refrigerator (2°-8°C): 24 hrs*.
*Once removed from the refrigerator, infusions should be completed within the room temperature (25±2°C) stability time, provided the total refrigeration time, time to reach room temperature (25±2°C) and infusion does not exceed refrigeration stability time.
+Dextrose 50 mg/mL (5%) solution for injection should not be used for infusion durations >1 hr.
Chemical and physical in-use stability has been demonstrated for the times and solutions shown previously.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hrs at 2°-8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
MIMS Class
ATC Classification
J01DH04 - doripenem ; Belongs to the class of carbapenems. Used in the systemic treatment of infections.
Vial 500 mg (white to slightly yellowish off-white crystalline powder for infusion) x 10's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in